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A novel mutation in SACS gene in a
family from southern Italy
C. Criscuolo, MD; S. Banfi, MD; M. Orio, MD; P. Gasparini, MD; A. Monticelli, MD; V. Scarano, MD;
F.M. Santorelli, MD; A. Perretti, MD; L. Santoro, MD; G. De Michele, MD; and A. Filla, MD
Abstract—A form of autosomal recessive spastic ataxia (ARSACS) has been described in the Charlevoix and Saguenay
regions of Quebec. So far a frameshift and a nonsense mutation have been identified in the SACS gene. The authors report
a new mutation (1859insC), leading to a frameshift with a premature termination of the gene product sacsin, in two
sisters from consanguineous parents. The phenotype is similar to previously described patients with ARSACS.
NEUROLOGY 2004;62:100–102
Autosomal recessive spastic ataxia of Charlevoix–
Saguenay (ARSACS; MIM 270550) is a neurodegen-
erative disorder showing pyramidal, cerebellar
progressive involvement and peripheral neuropathy.
More than 300 patients with ARSACS have been
described in the Charlevoix–Saguenay region of
northeastern Quebec, where the estimated carrier
frequency is 1 of every 22 persons.1 Main clinical
features include early-onset progressive ataxia, dys-
arthria, spasticity, nystagmus, retinal striation, and
distal amyotrophy. Imaging shows cerebellar vermis
atrophy, and peripheral nerve conduction studies re-
veal markedly decreased amplitude of the sensory
potentials and reduced motor conduction velocities.
The disease is pathologically characterized by atro-
phy of the upper cerebellar vermis and loss of Pur-
kinje cells.2
The gene responsible for ARSACS (SACS) maps to
chromosome 13q113 and has a single large exon
spanning 12,794 base pairs (bp),4 the largest exon in
any vertebrate organism. The SACS product is a pre-
dicted 3829 amino acid protein, sacsin, which proba-
bly exerts a chaperon-mediated protein-folding
activity.4 Until now, two causal mutations have been
described in this gene in the French-Canadian popu-
lation: g.6594 delT, resulting in a frameshift with
introduction of a stop codon, and g.5254 C3T, a
nonsense mutation.4 Ninety-four percent of the dis-
ease alleles carry the g.6594 delT; 3% carry the
g.5254 C3T; and the remaining 3% carry an un-
known mutation always in the heterozygous state
with g.6594 delT.5 Recently, one Tunisian and two
Turkish families have been linked to 13q11.6-8 The
presence and the frequency of this disease are not
known in most European countries. In this study, we
describe a novel single-base insertion mutation in
the SACS gene in two affected sisters from southern
Italy.
Methods. We recruited 22 index patients with an ARSACS-like
phenotype from a series of 85 patients from southern Italy with
early-onset cerebellar ataxia. Consanguinity was present in six
families. The inclusion criteria were sporadic or autosomal reces-
sive progressive ataxia, corticospinal signs (at least two among
brisk tendon reflexes, hypertonus, and Babinski signs), clinical
(decreased or absent ankle reflexes and decreased vibration sense)
or neurophysiologic signs of peripheral neuropathy, and negative
molecular test for Friedreich ataxia.
After informed consent was obtained from all patients,
genomic DNA was extracted from peripheral blood samples.
Primer pairs were designed to screen for the two French-
Canadian mutations in all patients using the web-based version of
the Primer 3.0 program. PCR products, subjected to electrophore-
sis in 1.5% agarose gel, were then analyzed by denaturing high-
performance liquid chromatography (DHPLC). DHPLC was
performed on a WAVE nucleic acid fragment analysis system
HSM (Transgenomic, Crewe, UK). The composition of buffer A
was 0.1 mol/L triethylammonium acetate (TEAA), pH 7.0, 0.025%
acetonitrile (v/v). Buffer B contained 0.1 mol/L TEAA, 25% aceto-
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nitrile (v/v). Analysis was carried out at a flow rate of 0.9 mL/min
and buffer B gradient increase of 2% per minute. Start and end
concentrations of buffer B were adjusted according to the size of
the PCR product. In addition, in the patients from consanguineous
marriages, linkage analysis was performed using polymorphic
markers spanning the SACS gene (D13S292, D13S787, D13S232,
D13S1275) to determine if the disease trait was associated with
the ARSACS locus. Patients homozygous for all tested markers
were considered in possible linkage to ARSACS and were screened
for mutations in the entire gene. The unique SACS exon, because
of the large size, was divided in 15 overlapping fragments of
approximately 800 bp. Oligonucleotide primer pairs and PCR con-
ditions are shown in the table available online (see table E-1 on
the Neurology Web site). The PCR reaction was carried out in a
total volume of 25 L containing 100 ng of genomic DNA, 2.5 L
10  PCR buffer containing MgCl2 (15 mmol/L), 2 L dNTP (2.5
mmol/L), 0.5 L each primer (20 pm/L), and 0.3 L “AmpliTaq
Gold” (Perkin-Elmer, Foster City, CA). PCR products were puri-
fied from agarose gels by the QIAGEN gel extraction kit (Hilden,
Germany) and directly sequenced, from the forward and reverse
strands, on an automated sequencer (ABI 3100; Applied Biosys-
tem, Weiterstadt, Germany) using the ABI-PRISM big-dye termi-
nator cycle sequencing ready reaction kit (Applied Biosystem).
Peripheral nerve conduction study was performed using needle
electrodes.
Results. We did not find any of the previously described
mutations in our patients. Conversely, linkage analysis
revealed that one patient from a consanguineous marriage
was homozygous for all tested markers suggesting linkage
to the ARSACS locus. The affected sister showed the same
haplotype (figure 1). Sequencing of the entire gene in both
sisters revealed a novel homozygous 1859insC mutation
(figure 2). The screening of this new mutation in the re-
maining patients was negative.
Clinical and neurophysiologic features of the two pa-
tients are summarized in the table. Onset was character-
ized by delay in walking, followed by gait unsteadiness and
tendency to fall. The patients, now aged in their 40s, need
support when walking. Mental retardation and hypoacusia
are present in Patient 2. Sural nerve biopsy, performed in
Patient 1, showed a severe loss of large myelinated fibers
(11 m) with almost normal total number of myelinated
fibers. Neuroimaging showed cerebellar atrophy more
marked in the vermis than in the hemispheres.
Discussion. We report a new mutation in the
SACS gene in two sisters from consanguineous par-
ents in southern Italy. The novel 1859insC mutation
results in a frameshift and the introduction of an
early stop codon at residue 599. The resulting pre-
dicted protein lacks 3230 amino acids. The French-
Figure 1. Pedigree and haplotypes for the autosomal re-
cessive spastic ataxia of Charlevoix–Saguenay (ARSACS)
locus.
Figure 2. Electropherogram of the SACS normal sequence
(A) and the novel single-base insertion [C] mutation in a
patient (B). The nucleotide position is based on the tran-
script GenBank accession number AF193556.
Table Clinical and neurophysiological findings
Patients 1 2
Onset age/disease duration, y 2/41 2/36




Lower limb spasticity  
Increased knee jerks  
Ankle jerks  
Babinski signs  
Lower limb amyotrophy  
IQ 74 58
Median nerve
SCV digit III-wrist, m/s 42.2 38.8
SAP at wrist, V 0.8 0.7
MCV elbow-wrist, m/s 41.6 40.2
SSEP N13–N20, m/s 10.7 10.8
Presence and severity of features:   mild to moderate;  
severe;   absent.
SCV  sensory conduction velocity (normal lower limit 51 m/s);
SAP  sensory action potential (normal lower limit 6 V);
MCV  motor conduction velocity (normal lower limit 54 m/s);
SSEP  somatosensory evoked potential (normal upper limit
7.4 m/s).
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Canadian g.6594T and g.5254C mutations also cause
the premature termination of the predicted protein.
The recessive character and the truncating nature of
the sacsin mutations suggest that the development
of the disease is associated with a loss of function.
Sacsin shows significant sequence similarity to pro-
teins and domains involved in chaperon-mediated
protein folding because it contains a “DnaJ” motif
and the N-terminal domain of the Hsp90.4 In addi-
tion, sacsin is characterized by the presence of two
leucine zipper and three coiled-coil domains and
seven nuclear localization signals.4 The mutation de-
scribed in this report is localized at the N-terminal
region before any known domain.
The proteins paraplegin and HSPD1, involved in
two forms of hereditary spastic paraplegias (SPG7 and
13), show chaperon-like activities.9,10 The corticospinal
tract involvement present in these two diseases is a
prominent feature in patients with ARSACS.
There are no phenotypic differences among the
patients homozygous for the g.6594delT, the com-
pound heterozygotes g.6594delT/g.5254C3T, and
g.6594delT/unknown mutation.5 Although the new
mutation leads to a shorter truncated protein, its
harmful effect is not increased. Our patients had
clinical and neurophysiologic findings similar to
those observed in the French-Canadian group except
for the presence of mental retardation in one patient.
Intellectual impairment was also observed in one of
the four Turkish patients linked to ARSACS locus.7
A finer genotype and phenotype correlation may be
possible when more mutations are identified.
This report confirms that ARSACS is present in
populations other than those previously described
and should be considered in patients with autosomal
recessive cerebellar ataxia, pyramidal signs, and pe-
ripheral neuropathy. Failure to detect g.6594delT
and g.5254C3T mutations in our series suggests
that these two mutations may be a rare cause of
ARSACS in southern Italy.
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